Approach — ParFay Nutraceuticals

Approach

Findings arrive early, when they are still cheap.

Engagements are project-based and sequenced so that the expensive discoveries happen on paper. Each phase consumes the output of the one before it, and any phase can end the engagement if the answer is that your product should not be made the way you planned. The full sequence runs to forty working days; a standalone review of an existing formula takes seven.

Days 1–2

Brief

We start from the commercial reality, not the ingredient list. What the product is for, who takes it, which markets it ships to, what dose form you have committed to, and what you intend to claim on the label. Constraints you already have — an existing CMO, a target cost, a launch date — are inputs, not obstacles to work around later.

You provide: Product concept, target markets, dose form, any existing formula or supplier
You receive: A written scope with the questions we think matter most, before any fee is agreed

Days 3–8

Screen

Every proposed active is screened against the evidence for the claim, the permitted lists and dose ceilings in each target market, and the interaction literature. This is where most formulas lose an ingredient or gain one. It is deliberately early: it is far cheaper to lose an ingredient now than after you have bought a tonne of it.

You provide: Nothing further — this phase is ours
You receive: A screen naming every ingredient that will not survive, and why

Days 9–22

Specification

The blueprint itself. Actives at defined dose and salt form, the excipient system that carries them, and the rationale for every line. Synergies are specified deliberately rather than hoped for; antagonisms are separated by design. Where two ingredients cannot coexist in one unit, we say so and specify the alternative.

You provide: Review and challenge — the specification improves under pressure
You receive: A line-by-line specification with rationale and references

Days 23–34

Manufacturability review

The specification is then tested against the line it will actually run on. Flow, compressibility, blend uniformity, hygroscopicity, overages to hold claim through shelf life. A formula that is pharmacologically correct and cannot be compressed is not finished, and this is the phase where that gets caught rather than discovered on a trial batch.

You provide: Your CMO's equipment and batch-size constraints, if a CMO is chosen
You receive: A risk assessment with a specified mitigation against each risk

Days 35–40

Handover

You receive a specification pack written for your manufacturer to work from, not a document that needs translating. Where you have not yet chosen a CMO, we shortlist manufacturers equipped for your form and volume, and specify the raw-material qualification and testing the product needs.

You provide: Your manufacturer, or a decision to have us find one
You receive: The pack your CMO needs, and the testing specification for incoming material

Engagement terms

Scope, fee and duration.

Basis

Project-based. Scope and fee are fixed in writing before work starts.

Typical duration

7 – 40 working daysSeven working days for a standalone formulation review; forty for the full five-phase engagement.

Fee

Quoted per project once scope is agreed.

Start with a brief What each phase delivers